Quote:
Originally posted by Mmmm, Burger (C.J.)
I am too, but drug companies aren't facing true "market" incentives right now, so to say that changing the current regulation is pareto inferior is not a forgone conclusion.
I don't think it would be too unreasonable , if one has a national Rx drug plan, to offer a price that is equal to an exchange-rate adjusted average price in the 7 largest industrial countries other than the US.
|
Yeah, but if they go with the Medicare drug plan model, the gov't won't be able to bargain with the drug companies on prices.
So, club, do you think there's any connection between Billy Tauzin getting that provision into the Medicare bill and him becoming the head lobbyist for the pharmeceutical companies' trade group? I guess that's a market too . . . . would be interesting to know how much he's getting paid. Apparently the guy who currently has the MPAA (or something to do with the film industry) lobbyist job, which Tauzin turned down to go with the drug companies, makes in excess of $1 million per year. Peanuts compared with the CEO of oh say Tyco or Enron, but compares well with congressional salaries.
